Contents: The amyloid plaque
Impact of delaying onset of AD
The amyloidocentric theory of Alzheimer's disease
Compelling evidence for the Abeta theory of AD
Delay onset of AD by 5 years
The best target for a disease-modifying drug
APP structure and domains
Iron-export ferroxidase activity of beta-amyloid precursor protein
Age at onset correlates with Abeta isoforms
Activation of PS1
Abeta amyloid
The mechanism of neurodegeneration
Abeta metal binding modes
Current working model of Abeta toxicity
Abeta amyloid protein: current model consistent with EXAFS
Metal-protein attenuating compound (MPAC) with moderate affinity for metals
Clioquinol (CQ, PBT1) the prototypic MPAC
PBT2: SAR based on rational drug design
CQ (PBT1) vs. PBT2
Alzheimer's disease Abeta-directed therapeutics in clinical development: drugs and biologics
Phase II results of Abeta targeting AD modifying drugs.